These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Therapy with growth hormone in pediatric patients with chronic kidney insufficiency].
    Author: Hämmerli I, Neuhaus T, Leumann E, Nüssli R, Vischer D, Zachmann M.
    Journal: Schweiz Med Wochenschr; 1994 Sep 10; 124(36):1575-80. PubMed ID: 7939524.
    Abstract:
    Statural growth in children with chronic renal failure (CRF) is often delayed. Several studies have shown that one of the main causes is partial resistance to growth hormone (GH), which can be overcome by supraphysiologic doses of recombinant human (rh) GH. Since August 1990 we have been treating 8 boys and 1 girl (ages 1.7-12.7, mean 5.3 yrs) with rhGH (4 IU/m2 s.c. daily). All patients were prepubertal and were 2.4-4.5 (mean 3.2) SDS below the mean normal height for age and sex. 5 patients were on dialysis. Mean growth velocity was -2.0 SDS (5.4 cm/yr) before and +2.6 SDS (9.5 cm/yr) during the first year of therapy with rhGH. Mean height increased from -3.2 to -2.5 SDS at 1 year. Height in the 4 boys treated > 2 yrs with rhGH improved from -3.3 SDS (before rhGH) to -2.4 (1st yr) and to -2.0 SDS (2nd yr); their height increased by 9.6 cm (1st yr) and 7.8 cm (2nd yr) as compared to 4.6 cm in the year before treatment. The response to rhGH was better in the 4 patients treated conservatively than in those on dialysis. Side effects did not occur. Plasma insulin increased but the oral glucose tolerance test remained normal. We conclude that treatment with rhGH represents an important step forward in selected pediatric patients with CRF. The excellent acceptance reflects the high expectations of the patients and their families.
    [Abstract] [Full Text] [Related] [New Search]